Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Zephyr Valve Registry (ZEVR)

← catalyst calendar

NCT04186546 · readout in 133 d

Sponsored by Pulmonx Corporation (industry) · LUNG — their whole pipeline →.

Phase
Status
Active, not recruiting
Study type
Observational
Enrollment
150estimated
Sites
11
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2019-11-25actualWhen the study began enrolling
Primary completion2026-12-31estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-12-31estimatedThe whole study's end, after follow-up
First posted2019-12-04actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-04-29actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Emphysema

Intervention

  • Device: Zephyr Valve Procedure — also filed as Zephyr Endobronchial Valve, Endobronchial Valve, Bronchoscopic Lung Volume Reduction, BLVR

Primary outcomes

what the primary-completion date above is the date OF
Incidence Rate of Pneumothorax from Baseline to 45-days post-procedure
measured Baseline to 45-days post-procedure
Incidence Rate of Serious Adverse Events (SAEs) of Interest from Baseline to 3 years post-procedure
measured Baseline to 3 years post-procedure

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · LUNG's whole pipeline · Catalyst calendar · Every registered study · What changed